Rigel Pharmaceuticals (RIGL) Cash from Investing Activities (2010 - 2026)

Rigel Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 24.42% year-over-year to -$8.0 million in Q1 2026; TTM through Mar 2026 was -$89.8 million, a 1233.16% decrease from a year earlier, with the FY2025 full-year figure at -$92.4 million, down 2336.44% from the prior year.
• Cash from Investing Activities improved to -$8.0 million in Q1 2026 per RIGL's latest filing, from -$25.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $22.6 million in Q1 2022 and bottomed at -$33.2 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is $313000.0 (2024), against an average of -$1.6 million.
• Across the five-year window, Cash from Investing Activities soared 424.96% in 2024 and plunged 3471.25% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $18.6 million in 2022, then tumbled by 136.96% to -$6.9 million in 2023, then sank by 58.77% to -$10.9 million in 2024, then sank by 132.38% to -$25.4 million in 2025, then soared by 68.56% to -$8.0 million in 2026.
• Per Business Quant, the three latest RIGL Cash from Investing Activities figures stand at -$8.0 million (Q1 2026), -$25.4 million (Q4 2025), and -$33.2 million (Q3 2025).